SIM
KNSA icon

Spark Investment Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Spark Investment Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20,800
Closed -$281K – 456
2019
Q2 		$281K Sell
20,800
-46,927
-69% -$728K 0.02% 428
2019
Q1 		$1.22M Buy
67,727
+47,727
+239% +$922K 0.06% 314
2018
Q4 		$561K Buy
+20,000
New +$417K 0.04% 377

Other funds holding KNSA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Spark Investment Management's KNSA Position: Q3 2019 in Review

Spark Investment Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2019, closing a stake of 20,800 shares — an estimated $281K sold.

Spark Investment Management first reported a position in KNSA in Q4 2018 and held it in 3 quarters. The position peaked at $1.22M in Q1 2019. 54 funds tracked by Wall St. Rank hold KNSA as of Q3 2019.

  • Spark Investment Management reported no remaining Kiniksa Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Spark Investment Management sold 20,800 Kiniksa Pharmaceuticals shares in Q3 2019, an estimated $281K.
  • Spark Investment Management first reported a position in Kiniksa Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Spark Investment Management's Kiniksa Pharmaceuticals position peaked at $1.22M in Q1 2019.
  • 54 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2019.

Based on Spark Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.